Skip to main content

Advertisement

Log in

Floating drug delivery systems: A review

  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The purpose of writing this review on floating drug delivery systems (FDDS) was to compile the recent literature with special focus on the principal mechanism of floatation to achieve gastric retention. The recent developments of FDDS including the physiological and formulation variables affecting gastric retention, approaches to design single-unit and multiple-unit floating systems, and their classification and formulation aspects are covered in detail. This review also summarizes the in vitro techniques, in vivo studies to evaluate the performance and application of floating systems, and applications of these systems. These systems are useful to several problems encountered during the development of a pharmaceutical dosage form.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hirtz J. The git absorption of drugs in man: a review of current concepts and methods of investigation.Br J Clin Pharmacol. 1985;19:77S-83S.

    CAS  Google Scholar 

  2. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate system for oral delivery to the gastrointestinal tract.Adv Drug Del Rev. 1998;34:191–219.

    Article  CAS  Google Scholar 

  3. Lenaerts VM, Gurny R. Gastrointestinal Tract-Physiological variables affecting the performance of oral sustained release dosage forms. In: Lenaerts V, Gurny R, eds.Bioadhesive Drug Delivery System. Boca Raton, FL: CRC Press; 1990.

    Google Scholar 

  4. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention.Pharm Res. 1997;14:815–819.

    Article  CAS  Google Scholar 

  5. Rednick AB, Tucker SJ. Sustained release bolus for animal husbandry. US patent 3 507 952. April 22, 1970.

  6. Davis SS, Stockwell AF, Taylor MJ, et al. The effect of density on the gastric emptying of single and multiple unit dosage forms.Pharm Res. 1986;3:208–213.

    Article  Google Scholar 

  7. Urguhart J, Theeuwes F. Drug delivery system comprising a reservoir containing a plurality of tiny pills. US patent 4 434 153. February 28, 1994.

  8. Mamajek RC, Moyer ES. Drug dispensing device and method. US Patent 4 207 890. June 17, 1980.

  9. Fix JA, Cargill R, Engle K. Controlled gastric emptying. III. Gastric residence time of a non-disintegrating geometric shape in human volunteers.Pharm Res. 1993;10:1087–1089.

    Article  CAS  Google Scholar 

  10. Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, Maincent P. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy.J Control Release. 1999;58:195–205.

    Article  CAS  Google Scholar 

  11. Groning R, Heun G. Oral dosage forms with controlled gastrointestinal transit.Drug Dev Ind Pharm. 1984;10:527–539.

    Article  Google Scholar 

  12. Groning R, Heun G. Dosage forms with controlled gastrointestinal passage—studies on the absorption of nitrofurantion.Int J Pharm. 1989;56:111–116.

    Article  Google Scholar 

  13. Desai S. A Novel Floating Controlled Release Drug Delivery System Based on a Dried Gel Matrix Network [master's thesis]. 1984 Jamaica, NY, St John's University.

    Google Scholar 

  14. Vantrappen GR, Peeters TL, Janssens J. The secretory component of interdigestive migratory motor complex in man.Scand J Gastroenterol. 1979;14:663–667.

    Article  CAS  Google Scholar 

  15. Wilson CG, Washington N. The stomach: its role in oral drug delivery. In: Rubinstein MH, ed.Physiological Pharmacetical: Biological Barriers to Drug Absorption. Chichester, UK: Ellis Horwood; 1989:47–70.

    Google Scholar 

  16. Desai S, Bolton S. A floating controlled release drug delivery system: in vitro- in vivo evaluation.Pharm Res. 1993;10:1321–1325.

    Article  CAS  Google Scholar 

  17. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention.J Control Release. 2000;63:235–259.

    Article  CAS  Google Scholar 

  18. Timmermans J, Andre JM. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy.J Pharm Sci. 1994;83:18–24.

    Article  CAS  Google Scholar 

  19. Mojaverian P, Ferguson RK, Vlasses PH, et al. Estimation of gastric residence time of the Heidelberg capsules in humans: effect of varying food composition.Gastroenterology. 1985;89:392–397.

    CAS  Google Scholar 

  20. Bechgaard H, Ladefoged K. Distribution of pellets in gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets.J Pharm Pharmacol. 1978;30:690–692.

    CAS  Google Scholar 

  21. Garg S, Sharma S.Gastroretentive drug delivery systems. Business Briefing: Pharmatech 2003 Web Site. 5 th edition. May 2003. Available at: http://www.touchbriefings.com/cdps/cditem.cfm?NID=17&CID=5. Accessed: October 6, 2005.

  22. Timmermans J, Gansbeke VB, Moes AJ. Assessing by gamma scintigraphy the in vivo buoyancy of dosage forms having known size and floating force profiles as a function of time. Vol I.Proceedings of the 5th International Conference on Pharmacy Technology. Paris, France APGI. 1989, 42–51.

    Google Scholar 

  23. Yang L, Fassihi R. Zero order release kinetics from self correcting floatable configuration drug delivery system.J Pharm Sci. 1996;85:170–173.

    Article  CAS  Google Scholar 

  24. Burns SJ, Attwood D, Barnwell SG. Assessment of a dissolution vessel designed for use with floating and erodible dosage forms.Int J Pharm. 1998;160:213–218.

    Article  CAS  Google Scholar 

  25. Joseph NJ, Laxmi S, Jayakrishnan A. A floating type oral dosage from for piroxicam based on hollow microspheres: in vitro and in vivo evaluation in rabbits.J Control Release. 2002;79:71–79.

    Article  CAS  Google Scholar 

  26. Sheth PR, Tossounian JL. Sustained release pharmaceutical capsules. US patent 4,126,672. November 21, 1978.

  27. Soppimath KS, Kulkarni AR, Rudzinski WE, Aminabhavi TM. Microspheres as floating drug delivery system to increase the gastric residence of drugs.Drug Metab Rev. 2001;33:149–160.

    Article  CAS  Google Scholar 

  28. Ichikawa M, Watanabe S, Miyake Y. A new multiple unit oral floating dosage system. I: Preparation and in vitro evaluation of floating and sustained-release kinetics.J Pharm Sci. 1991;80:1062–1066.

    Article  CAS  Google Scholar 

  29. Ichikawa M, Watanabe S, Miyake Y. Granule remaining in stomach. US patent 4 844 905. July 4, 1989.

  30. Yang L, Esharghi J, Fassihi R. A new intra gastric delivery system for the treatment of helicobacter pylori associated gastric ulcers: in vitro evaluation.J Control Release. 1999;57:215–222.

    Article  CAS  Google Scholar 

  31. Ozdemir N, Ordu S, Ozkan Y. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluation of bilayer tablet formulation.Drug Dev Ind Pharm. 2000;26:857–866.

    Article  CAS  Google Scholar 

  32. Choi BY, Park HJ, Hwang SJ, Park JB. Preparation of alginate beads for floating drug delivery: effects of CO2 gas forming agents.Int J Pharm. 2002;239:81–91.

    Article  CAS  Google Scholar 

  33. Li S, Lin S, Daggy BP, Mirchandani HL, Chien TW. Effect of formulation variables on the floating properties of gastric floating drug delivery system.Drug Dev Ind Pharm. 2002;28:783–793.

    Article  CAS  Google Scholar 

  34. Li S, Lim S, Chien TW, Daggy BP, Mirchandani HL. Statistical optimization of gastric floating system for oral controlled delivery of calcium.AAPS PharmSciTech. 2001;2:E1.

    Article  CAS  Google Scholar 

  35. Penners G, Lustig K, Jorg PVG. Expandable pharmaceutical forms. US patent 5 651 985. July 29, 1997.

  36. Fassihi R, Yang L. Controlled release drug delivery systems. US patent 5 783 212. July 21, 1998.

  37. Talwar N, Sen H, Staniforth JN. Orally administered controlled drug delivery system providing temporal and spatial control. US patent 6 261 601. July 17, 2001.

  38. Michaels AS, Bashwa JD, Zaffaroni A. Integrated device for administering beneficial drug at programmed rate. US patent 3 901 232. August 26, 1975.

  39. Michaels AS. Drug delivery device with self actuated mechanism for retaining device in selected area. US patent 3 786 813. January 22, 1974.

  40. Baumgartner S, Kristel J, Vreer F, Vodopivec P, Zorko B. Optimisation of floating matrix tablets and evaluation of their gastric residence time.Int J Pharm. 2000;195:125–135.

    Article  CAS  Google Scholar 

  41. Moursy NM, Afifi NN, Ghorab DM, El-Saharty Y. Formulation and evaluation of sustained release floating capsules of Nicardipine hydrochloride.Pharmazie. 2003;58:38–43.

    CAS  Google Scholar 

  42. Atyabi F, Sharma HL, Mohammed HAH, Fell JT. In vivo evaluation of a novel gastro retentive formulation based on ion exchange resins.J Control Release. 1996;42:105–113.

    Article  CAS  Google Scholar 

  43. Thanoo BC, Sunny MC, Jayakrishnan A. Oral sustained release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluids.J Pharm Pharmacol. 1993;45:21–24.

    CAS  Google Scholar 

  44. Nur AO, Zhang JS. Captopril floating and/or bioadhesive tablets: design and release kinetics.Drug Dev Ind Pharm. 2000;26:965–969.

    Article  CAS  Google Scholar 

  45. Bulgarelli E, Forni F, Bernabei MT. Effect of matrix composition and process conditions on casein gelatin beads floating properties.Int J Pharm. 2000;198:157–165.

    Article  CAS  Google Scholar 

  46. Whitehead L, Collett JH, Fell JT. Amoxycillin release from a floating dosage form based on alginates.Int J Pharm. 2000;210:45–49.

    Article  CAS  Google Scholar 

  47. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density foam powder: effect of formulation and processing parameters on drug release.Eur J Pharm Sci. 2003;18:37–45.

    Article  CAS  Google Scholar 

  48. Asmussen B, Cremer K, Hoffmann HR, Ludwig K, Roreger M. Expandable gastroretentive therapeutic system with controlled active substance release in gastrointestinal tract. US patent 6 290 989. September 18, 2001.

  49. El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Preparation and evaluation of ketoprofen floating oral drug delivery system.Int J Pharm. 2001;220:13–21.

    Article  CAS  Google Scholar 

  50. Illum L; Ping H. Gastroretentive controlled release microspheres for improved drug delivery. US patent 6 207 197. March 27, 2001.

  51. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder.Int J Pharm. 2002;241:279–292.

    Article  CAS  Google Scholar 

  52. Sheth PR, Tossounian JL. Novel sustained release tablet formulations. 4 167 558. September 11, 1979.

  53. Ushomaru K, Nakachimi K, Saito H. Pharmaceutical preparations and a method of manufacturing them. US patent 4 702 918. October 27, 1987.

  54. Bolton S, Desai S. Floating sustained release therapeutic compositions. US patent 4 814 179. March 21, 1989.

  55. Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Preparation of multiple unit hollow microspheres (microballoons) with acrylic resins containing tranilast and their drug release characteristics (in vivo).J Control Release. 1991;16:279–290.

    Article  CAS  Google Scholar 

  56. Dennis A, Timminis P, Lel K. Buoyant controlled release powder formulation. US patent 5 169 638. December 8, 1992.

  57. Spickett RGW, Vidal JLF, Escoi JC. Antacid preparation having prolonged gastric residence. US patent 5,288,506. February 22, 1993.

  58. Franz MR, Oth MP. Sustained release, bilayer buoyant dosage form. US patent 5 232 704. August 3, 1993.

  59. Wu W, Zhou Q, Zhang HB, Ma GD, Fu CD. Studies on nimodipine sustained release tablet capable of floating on gastric fluids with prolonged gastric resident time.Yao Xue Xue Bao. 1997;32:786–790.

    CAS  Google Scholar 

  60. Wong PSL, Dong LC, Edgren DE, Theeuwes F. Prolonged release active agent dosage form adapted for gastric retention. US patent 6 120 803. September 19, 2000.

  61. Mitra SB. Sustained release oral medicinal delivery device. US patent 4 451 260. May 29, 1984.

  62. Harrigan BM. Drug delivery device for preventing contact of undissolved drug with the stomach lining. US patent 4 055 178. October 25, 1977.

  63. Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release.Eur Neurol. 1987;27:215–275.

    Article  Google Scholar 

  64. Sheth PR, Tossounian J. The hydrodynamically balanced systems (HBS): a novel drug delivery system for oral use.Drug Dev Ind Pharm. 1984;10:313–339.

    Article  CAS  Google Scholar 

  65. Degtiareva H, Bogdanov A, Kahtib Z, etal.. The use of third generation antacid preparations for the treatment of patients with nonulcerous dyspeosia and peptic ulcer complicated by reflux esophagus [in Chinese].Liakrs' ka sprava. 1994;5–6:119–122.

    Google Scholar 

  66. Fabregas JL, Claramunt J, Cucala J, Pous R, Siles A. In vitro testing of an antacid formulation with prolonged gastric residence time (Almagate flot coat).Drug Dev Ind Pharm. 1994;20:1199–1212.

    Article  CAS  Google Scholar 

  67. Washington N, Washington C, Wilson CG, Davis SS. What is liquid Graviscon? A comparison of four international formulations.Int J Pharm. 1986;34:105–109.

    Article  CAS  Google Scholar 

  68. Katayama H, Nishimura T, Ochi S, Tsuruta Y, Yamazaki Y. Sustained release liquid preparation using sodium alginate for eradication ofHelicobacter pylori.Biol Pharm Bull. 1999;22:55–60.

    CAS  Google Scholar 

  69. Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric floating and sustained release preparation. 1. Application of calcium silicate as floating carrier.Chem Pharm Bull (Tokyo). 1996;44:1361–1366.

    CAS  Google Scholar 

  70. Kohri N, Naasani I, Iseki K. Improving the oral bioavailability of sulphiride by a gastric retained form in rabbits.J Pharm Pharmacol. 1995;48:371–374.

    Google Scholar 

  71. Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained release floating dosage form of amoxycillin trihydrate.Int J Pharm. 1992;86:79–88.

    Article  CAS  Google Scholar 

  72. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Hollow micropheres for use as a floating controlled drug delivery system in stomach.J Pharm Sci. 1992;81:135–140.

    Article  CAS  Google Scholar 

  73. Mazer N, Abhisch E, Gfeller JC, etal.. Intragastric behaviour and absorption kinetics of a normal and floating modified release capsules of isardipine under fasted and fed conditions.J Pharm Sci. 1988; 77:647–657.

    Article  CAS  Google Scholar 

  74. Hashim H, Li WPA. Improving the release characteristics of water soluble drugs from hydrophilic sustained release matrices b in situ gas generation.Int J Pharm. 1987;35:201–209.

    Article  CAS  Google Scholar 

  75. Chen GL, Hao WH. In vitro performance of floating sustained release capsules of verapamil.Drug Dev Ind Pharm. 1998;24:1067–1072.

    CAS  Google Scholar 

  76. Ichikawa M, Watanabe S, Miyake Y. A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with para amino benzoic acid and iso sorbide di nitrate as model drugs.J Pharm Sci. 1991;80:1153–1156.

    Article  CAS  Google Scholar 

  77. Cheuh HR, Zia H, Rhodes CT. Optimization of Sotalol floating and bioadhesive extended release tablet formulation.Drug Dev Ind Pharm. 1995;21:1725–1747.

    Article  Google Scholar 

  78. USP 28 NF 23. Rockville, MD: US Pharmacopeia; 2005:2413.

  79. Pillay V, Fassihi R. Evaluation and comparision of dissolution data derived from different modified release dosage forms: an alternative method.J Control Release. 1998;55:45–55.

    Article  CAS  Google Scholar 

  80. Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Hollow microspheres for use as floating controlled drug delivery system in stomach.J Pharm Sci. 1992;81:135–140.

    Article  CAS  Google Scholar 

  81. Sakuma S, Sudo R, Suzuki N, Kikuchi H, Akashi M, Hayashi M. Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in gastrointestinal tract.Int J Pharm. 1999;177:161–172.

    Article  CAS  Google Scholar 

  82. Babu VBM, Khar RK. In vitro and In vivo studies of sustained release floating dosage forms containing salbutamol sulphate.Pharmazie. 1990;45:268–270.

    CAS  Google Scholar 

  83. Chen J, Blevins WE, Park H, Park K. Gastric retention properties of superporous hydrogel composites.J Control Release. 2000;64:39–51.

    Article  CAS  Google Scholar 

  84. Menon A, Ritschel WA, Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide.J Pharm Sci. 1994; 83:239–245.

    Article  CAS  Google Scholar 

  85. Whitehead L, Fell JT, Collett JH, Sharma HL, Smith A. In vivo study demonstrating prolonged gastric retention.J Control Release. 1998;55:3–12.

    Article  CAS  Google Scholar 

  86. Oth M, Franz M, Timmermans J, Moes A. The bilayer floating capsule: a stomach directed drug delivery system for misoprostal.Pharm Res. 1992;9:298–302.

    Article  CAS  Google Scholar 

  87. Miyazaki S, Yamaguchi H, Yokouchi C, Takada M, Huo WM. Sustained release and intra gastric floating granules of indomethacin using chitosan in rabbits.Chem Pharm Bull (Tokyo). 1988;36: 4033–4038.

    CAS  Google Scholar 

  88. Malcolm SL, Allen JG, Bird H, etal.. Single dose pharmacokinetics of Madopar HBS in volunteers.Eur Neurol. 1987;27:28S-35S.

    Article  Google Scholar 

  89. Rouge N, Allémann E, Gex-Fabry M, et al. Comparative pharmacokinetic study of a floating multiple unit capsule, a high density multiple unit capsule and an immediate release tablet containing 25 mg atenolol.Pharm Acta Helv. 1998;73:81–87.

    Article  CAS  Google Scholar 

  90. Crevoisier C, Hoevels B, Zurcher G, Da Prada M. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.Eur Neurol. 1987;27:36S-46S.

    Article  Google Scholar 

  91. Marion MH, Stochi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD. Single dose studies of a slow release preparation of Levodopa and benserazide (Madopar HBS) in Parkinson's disease.Eur Neurol. 1987;27:54S-58S.

    Article  Google Scholar 

  92. Cook JD, Carriaga M, Kahn SG, Schalch W, Skikne BS. Gastric delivery system for ion supplementation.Lancet. 1990;335:1136–1139.

    Article  CAS  Google Scholar 

  93. Blaser MJ. Hypothesis on the pathogenesis and natural history ofHelicobacter pylori induced inflammation.Gastroenterology. 1992; 102:720–727.

    CAS  Google Scholar 

  94. Gibaly EI. Development and evaluation of novel floating chitosan microcapsules: comparision with non floating chitosan microspheres.Int J Pharm. 2002;249:39–47.

    Article  Google Scholar 

  95. Sato Y, Kawashima Y. In vitro and in vivo evaluation of riboflavin containing microballoons for a floating controlled drug delivery system in healthy human volunteers.J Control Release. 2003;93: 39–47.

    Article  CAS  Google Scholar 

  96. Shimpi S, Chauhan B, Mahadik KR, Paradkar A. Preparation and evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation.AAPS PharmSciTech. 2004;5: E43.

    Article  Google Scholar 

  97. Dave BS, Amin AF, Patel MM. Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation.AAPS PharmSciTech. 2004;5:E34.

    Article  Google Scholar 

  98. Sriamornsak P, Thirawong N, Puttipipatkhachorn S. Morphology and buoyancy of oil-entrapped calcium pectinate gel beads.The AAPS Journal. 2004;6:E24.

    Article  Google Scholar 

  99. Reddy L, Murthy R. Floating dosage systems in drug delivery.Crit Rev Ther Drug Carrier Syst. 2002;19:553–585.

    Article  CAS  Google Scholar 

  100. Chitnis V, Malshe VS, Lalla JK. Bioadhesive polymers synthesis, evaluation and application in controlled release tablets.Drug Dev Ind Pharm. 1991;17:879–892.

    Article  CAS  Google Scholar 

  101. Rouge N, Leroux JC, Cole ET, Doelker E, Buri P. Prevention of sticking tendency of floating mini tablets filled into hard gelatin capsules.Eur J Pharm Biopharm. 1997;43:165–171.

    Article  CAS  Google Scholar 

  102. Phuapradit W. Influence of Tablet Buoyancy on Oral Absorption of Sustained Release Acetaminophen Matrix Tablets [dissertation]. 1989, Jamaica, NY, St John's University.

    Google Scholar 

  103. Phuapradit W, Bolton S. Influence of tablet density on oral absorption of sustained release acetaminophen matrix tablets.Drug Dev Ind Pharm. 1991;17:1097–1107.

    Article  CAS  Google Scholar 

  104. Gupta SK. Stability studies of ampicillin floating tablets (Ampiflot) and buffered Ampiflot [master's thesis]. 1987, Jamaica, NY, St John's University.

    Google Scholar 

  105. Machida Y, Inouye K, Tokumura T, Iwata M, Nagai T. Preparation and evaluation of intragastric buoyant preparations.Drug Des Deliv. 1989;4:155–161.

    CAS  Google Scholar 

  106. Gu TH, Chen SX, Zhu JB, Song DJ, Guo JZ, Hou JM. Pharmacokinetics and pharmacodynamics of diltiazem floating tablets [in Chinese]Chung Kao Yao Li Hsuesh Pao. 1992;13:527–531.

    CAS  Google Scholar 

  107. Watanbe K, Machida Y, Takayama M, Iwta M, Nagai T. Preparation and evaluation of intragastric floating tablets having pH independent buoyancy and sustained release property.Arch Pract Pharm Yakuzaigaku. 1993;53:1–7.

    Google Scholar 

  108. Rouge N, Cole ET, Doelker E, Buri P. Buoyancy and drug release patterns of floating minutesitablets containing piretanide and atenolol as model drugs.Pharm Dev Technol. 1998;3:73–84.

    Article  CAS  Google Scholar 

  109. Inouye K, Machida Y, Sannan T, Nagai T. Buoyant sustained release tablets based on chitosan.Drug Des Deliv. 1988;2: 165–175.

    CAS  Google Scholar 

  110. Inagni HM, Timmermans J, Moes AJ. Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit.Int J Pharm. 1987;35:157–164.

    Article  Google Scholar 

  111. Gustafson JH, Weissman L, Weinfeld RE, Holazo AA, Khoo KC, Kalpan SA. Clinical bioavailability evaluation of a controlled release formulation of diazepam.J Pharmacokinet Biopharm. 1981;9:679–691.

    Article  CAS  Google Scholar 

  112. Khattar D, Ahuja A, Khar RK. Hydrodynamically balanced systems as sustained release dosage form for Propranalol hydrochloride.Pharmazie. 1990;45:356–358.

    CAS  Google Scholar 

  113. Simoni P, Cerre C, Cipolla A, etal.. Bioavailability study of a new sinking, enteric coated ursodeoxycholic acid formulation.Pharmacol Res. 1995;31:115–119.

    Article  CAS  Google Scholar 

  114. Jayanthi G, Jayaswal SB, Srivastava AK. Formulation and evaluation of terfenadine microballoons for oral controlled release.Pharmazie. 1995;50:769–770.

    CAS  Google Scholar 

  115. Inouye K, Machida Y, Sannan T, Nagai T. Buoyant sustained release tablets based on chitosan.Drug Des Deliv. 1989;4: 55–67.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shweta Arora.

Additional information

Published: October 19, 2005

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arora, S., Ali, J., Ahuja, A. et al. Floating drug delivery systems: A review. AAPS PharmSciTech 6, 47 (2005). https://doi.org/10.1208/pt060347

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1208/pt060347

Keywords

Navigation